Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in
  • Log out

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
  • Log out
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

March 14, 2006; 66 (5) Brief Communications

Thrombolytic therapy of acute ischemic stroke during pregnancy

A. Murugappan, W. M. Coplin, A. N. Al-Sadat, K. J. McAllen, L. H. Schwamm, L. R. Wechsler, C. S. Kidwell, J. L. Saver, S. Starkman, Y. P. Gobin, G. Duckwiler, M. Krueger, G. Rordorf, J. P. Broderick, G. E. Tietjen, S. R. Levine
First published March 13, 2006, DOI: https://doi.org/10.1212/01.wnl.0000201272.90216.15
A. Murugappan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
W. M. Coplin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. N. Al-Sadat
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
K. J. McAllen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
L. H. Schwamm
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
L. R. Wechsler
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. S. Kidwell
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. L. Saver
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. Starkman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Y. P. Gobin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G. Duckwiler
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Krueger
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G. Rordorf
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. P. Broderick
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G. E. Tietjen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. R. Levine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Thrombolytic therapy of acute ischemic stroke during pregnancy
A. Murugappan, W. M. Coplin, A. N. Al-Sadat, K. J. McAllen, L. H. Schwamm, L. R. Wechsler, C. S. Kidwell, J. L. Saver, S. Starkman, Y. P. Gobin, G. Duckwiler, M. Krueger, G. Rordorf, J. P. Broderick, G. E. Tietjen, S. R. Levine
Neurology Mar 2006, 66 (5) 768-770; DOI: 10.1212/01.wnl.0000201272.90216.15

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
956

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Abstract

The authors report eight pregnant women with acute ischemic stroke treated with thrombolysis (rt-PA [recombinant human tissue plasminogen activator] or urokinase). Seven women recovered. Two extracranial and two asymptomatic intracranial hemorrhages complicated treatment; one woman died of arterial dissection complicating angiography. Three patients had therapeutic abortions, two fetuses were miscarried, and two babies were delivered healthy. Although pregnant women may be treated safely with thrombolytics, risks and benefits to mother and fetus must be carefully weighed.

Increased risk of stroke during pregnancy is controversial,1,2 and there is inadequate information regarding the use of thrombolytics in pregnant women. The package insert for recombinant human tissue plasminogen activator (rt-PA) (Activase) denotes pregnancy to be a relative contraindication for administration of the drug and labels rt-PA as pregnancy category C (uncertain safety). Others denote it to be pregnancy category B (presumed safety based on animal studies).3 Urokinase (UK) is classified as pregnancy category B. We report a series of eight patients who underwent thrombolysis for acute ischemic stroke (AIS) during pregnancy. We also attempt to clarify the maternal safety and efficacy of rt-PA in pregnant women.

Methods.

When a pregnant woman presented within 3 hours of the onset of AIS, we communicated with 96 colleagues at 40 medical centers in four countries regarding whether any had treated a pregnant woman with rt-PA for AIS. Colleagues included those with a professed academic and clinical interest in AIS therapy, or neurologic and neurosurgical emergency and critical care. We received notice of eight other cases from this selected group of physicians. One of these cases was unavailable for report here.

We queried contributors regarding clinical presentation, NIH Stroke Scale (NIHSS) score, medical history, suspected etiology of the index stroke, details of treatment course (including complications, if any), and clinical outcomes of mothers and fetuses. The NIHSS was recorded before and after treatment and at the most recent available patient follow-up.

We searched the National Library of Medicine's MEDLINE database from 1966 until June 2005 using the medical subject headings of thrombolytics in pregnancy, rt-PA in pregnancy, and stroke in pregnancy. Additionally, we queried Genentech for any reports to the company regarding the use of this drug for ALS in pregnant women.

Results.

We identified a total of eight women treated with thrombolytics for AIS during pregnancy. Specific details are summarized in the table. Brief vignettes of the eight patients are available (appendix E-1, available on the Neurology Web site at www.neurology.org). Genentech, Inc. denoted no reports to the manufacturer of rt-PA use for AIS during pregnancy.

View this table:
  • View inline
  • View popup
  • Download powerpoint

Table Summary of patients in the current series

The average maternal age was 32 years, and the mean gestational age was 11 weeks, ranging from 4 to 37 weeks. Seven of the mothers were in their first trimester, and one was in the third trimester. The etiologies of their strokes were discontinuation of anticoagulants in two mechanical heart valve patients because of nausea in one and inability to afford low-molecular-weight heparin in the other; and hypercoagulable state in five patients, with a patent foramen ovale in one of these women and polycythemia vera with thrombocytosis in another. One patient had bacterial endocarditis. Three patients received IV rt-PA; in two of these, the treating physicians were unaware of the pregnancy, and of these two, one received rt-PA because of time constraints before the results of a urine pregnancy test were available from the laboratory, and in the other patient, a pregnancy test was not performed because of the patient's miscalculation of her last menstrual period. One patient received intra-arterial rt-PA in an effort to reduce fetal exposure. Four patients received UK, one for midbasilar total occlusion, one locally into the left middle cerebral artery, and two into the cerebral venous sinuses for cerebral venous thrombosis.

With one exception, mothers recovered well from their strokes. Adverse outcomes in these eight mothers included one intrauterine hematoma (drained), one buttock hematoma (managed conservatively), two asymptomatic small intracranial hemorrhages (one at a catheter site and one intraparenchymal, both after local UK), and one fatal malignant infarction as a result of arterial dissection complicating angioplasty (representing the only poor maternal outcome). This death cannot be attributed solely and directly to thrombolytic therapy. There were no symptomatic intracerebral hemorrhages (ICHs). Of the seven surviving mothers (87.5%), three elected to have therapeutic abortions. There were two miscarriages, both during the first trimester, 2 to 3 days after UK administration. Autopsy in one of these fetuses revealed lethal chromosomal anomalies. Autopsy was not performed in the other fetus, and it was presumed to be a spontaneous first trimester abortion. Two babies were delivered at term without any complications (one each intra-arterial [IA] rt-PA and IA UK).

The literature review identified 175 pregnant women treated with any thrombolytic, all but 3 for diseases other than stroke. We identified 12 pregnant women, with enough useful details reported, who were treated specifically with rt-PA for myocardial infarction and thromboembolic diseases other than stroke. Of the 12 fetuses, 6 (50%) were healthy after delivery, 1 died after delivery (see below), and 1 died because of emergent medical termination of pregnancy; in 3 of the reports, fetal outcome was not clearly stated. Overall, 6 of the 12 babies were delivered preterm electively based on maternal interest, and all of these babies, except 1, were healthy. One preterm baby delivered at 35 weeks of gestation, by caesarean delivery, died on day 14 of respiratory distress syndrome; autopsy revealed cerebral, cerebellar, and subarachnoid hemorrhages (12 full references available in appendix E-2).

Of the three cases reporting intra-arterial rt-PA treatment for stroke during pregnancy,4–6 two were first trimester,4,5 and one was third trimester.6 Two women had marked neurologic improvement,4,6 and one initially improved (recanalized the M1 segment), then worsened (small ICH), then further deteriorated (larger ICH), and then partially improved.5 All had normal babies delivered.

Discussion.

Based on these case summaries and reports obtained from literature, it seems that pregnant women generally can be safely treated with IV or IA rt-PA, or UK for AIS and can (but not always) have reasonably good outcomes. Effects on fetal viability and any potential complications of thrombolytics (e.g., teratogenicity) remain largely unknown. This series of eight patients is too small a number to draw any major efficacy or safety conclusions.

The major obstetric concern regarding the use of thrombolytics during pregnancy is their effect on the placenta, possibly resulting in premature labor, placental abruption, or fetal demise. A summary of the literature regarding thrombolytic (rt-PA, urokinase, etc.) use in pregnancy identified 172 pregnant women affected with thromboembolic conditions who were treated with thrombolytics7; however, none of these patients were treated for stroke. In that review, 5% to 8% of deliveries from patients treated with thrombolytics occurred preterm, which is within the reported 10% incidence of all preterm deliveries in the United States.8

Other concerns include hemorrhage during parturition or caesarean delivery. This risk exists if the patient goes into labor within the context sensitive half-time (the time of the drug's effective physiologic and pharmacologic effects in the setting of the disease process being studied) after administration of the thrombolytic.

Regarding teratogenicity, there are no data in the literature or any reports to the manufacturer regarding this issue, either for rt-PA or for UK. One might consider that the teratogenic effect, if any, might be less with IA rt-PA use, because the dose of IA rt-PA is less than the IV dose.

The ethical situation of a young woman being less disabled as a result of thrombolytics for AIS vs the risk (teratogenicity, prematurity, death) of the unborn baby must be considered in each clinical situation.

Acknowledgment

The authors thank J.J. King, K. Smoot, and M.E. Redman for assistance with cases. They also thank Dr. Jose Biller for supplying references pertinent to the investigation.

Footnotes

  • Additional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the Table of Contents for the March 14 issue to find the title link for this article.

    Supported in part by NIH grants NS 38905 (W.M.C.) and 43992 (S.R.L.).

    Disclosure: The authors report no conflicts of interest.

    Received June 30, 2005. Accepted in final form November 28, 2005.

References

  1. 1.↵
    Kittner SJ, Stern BJ, Feeser BR, et al. Pregnancy and the risk of stroke. N Engl J Med 1996;335:768–774.
    OpenUrlCrossRefPubMed
  2. 2.
    James AH, Bushnell CD, Jamison MG, Myers ER. Incidence and risk factors for stroke in pregnancy and the puerperium. Obstet Gynecol 2005;106:509–516.
    OpenUrlCrossRefPubMed
  3. 3.↵
    Briggs GGFR, Yaffe SJ. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. 5th ed. Baltimore: Williams & Wilkins, 1998.
  4. 4.↵
    Dapprich M, Boessenecker W. Fibrinolysis with alteplase in a pregnant woman with stroke. Cerebrovasc Dis 2002;13:290.
    OpenUrlCrossRefPubMed
  5. 5.↵
    Elford K, Leader A, Wee R, Stys PK. Stroke in ovarian hyperstimulation syndrome in early pregnancy treated with intra-arterial rt-PA. Neurology 2002;59:1270–1272.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    Johnson DM, Kramer DC, Cohen E, Rochon M, Rosner M, Weinberger J. Thrombolytic therapy for acute stroke in late pregnancy with intra-arterial recombinant tissue plasminogen activator. Stroke 2005;36:e53–e55.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    Turrentine MA, Braems G, Ramirez MM. Use of thrombolytics for the treatment of thromboembolic disease during pregnancy. Obstet Gynecol Surv 1995;50:534–541.
    OpenUrlCrossRefPubMed
  8. 8.↵
    Cooper LG. Effect of maternal age on birth outcomes among young adolescents. Social Biol 1995;42:22–35.
    OpenUrlPubMed

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • Methods.
    • Results.
    • Discussion.
    • Acknowledgment
    • Footnotes
    • References
  • Figures & Data
  • Info & Disclosures
Advertisement

Hemiplegic Migraine Associated With PRRT2 Variations A Clinical and Genetic Study

Dr. Robert Shapiro and Dr. Amynah Pradhan

► Watch

Topics Discussed

  • All Clinical trials
  • All Cerebrovascular disease/Stroke
  • Infarction
  • Clinical trials Observational study (Cohort, Case control)

Alert Me

  • Alert me when eletters are published
Neurology: 100 (5)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise